1. Home
  2. STRO vs FLC Comparison

STRO vs FLC Comparison

Compare STRO & FLC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sutro Biopharma Inc.

STRO

Sutro Biopharma Inc.

N/A

Current Price

$8.76

Market Cap

159.5M

Sector

Health Care

ML Signal

N/A

Logo Flaherty & Crumrine Total Return Fund Inc

FLC

Flaherty & Crumrine Total Return Fund Inc

N/A

Current Price

$15.47

Market Cap

162.4M

Sector

Finance

ML Signal

N/A

Company Overview

Basic Information
Metric
STRO
FLC
Founded
2003
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Trusts Except Educational Religious and Charitable
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
159.5M
162.4M
IPO Year
2018
2003

Fundamental Metrics

Financial Performance
Metric
STRO
FLC
Price
$8.76
$15.47
Analyst Decision
Strong Buy
Analyst Count
14
0
Target Price
★ $44.69
N/A
AVG Volume (30 Days)
★ 291.0K
20.3K
Earning Date
11-12-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
N/A
★ N/A
Revenue
★ $38,419,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$0.72
$15.33
52 Week High
$43.85
$18.09

Technical Indicators

Market Signals
Indicator
STRO
FLC
Relative Strength Index (RSI) 35.40 42.88
Support Level $8.11 $15.40
Resistance Level $10.77 $16.15
Average True Range (ATR) 0.85 0.19
MACD 0.14 -0.02
Stochastic Oscillator 17.01 9.46

Price Performance

Historical Comparison
STRO
FLC

About STRO Sutro Biopharma Inc.

Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. Company's wholly-owned product candidate is STRO-004, a single homogeneous ADC directed against tissue factor which are developing for the treatment of solid tumors. The company also pipeline contains STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.

About FLC Flaherty & Crumrine Total Return Fund Inc

Flaherty & Crumrine Total Return Fund Inc is a diversified, closed-end investment management company. Its investment objective is to provide its common shareholders with a high current income. The fund's secondary investment objective is capital appreciation.

Share on Social Networks: